Peptide Synthesis Market – Global Key Players & Growth Strategies Adopted by Them

PUNE, India, 2021-Jun-23 — /EPR Network/ —

Expected Revenue Growth:

The peptide synthesis market is projected to reach USD 426.4 million by 2023 from USD 310.5 million in 2018, at a CAGR of 6.5% during the forecast period.

Growth Boosting Factors:

Market growth can be attributed to increasing use of peptides in pharmaceutical drugs, increase in research activities and availability of funding for R&D, and the development of advanced peptide synthesizers. The base year considered for the study is 2017, and the forecast has been provided for the period between 2018 and 2023.

Global Leaders:

The global peptide synthesis market is a fragmented market. GenScript Biotech Corporation (China), Merck KGAA (Germany), AAPPTec (US), Bachem (Switzerland), and Biotage (Sweden) dominated the global peptide synthesis market in 2017.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=158927365

GenScript Biotech Corporation

GenScript accounted for the largest share of the market in 2017. The company has a broad product/services portfolio in peptide synthesis market and focuses on research and development activities to enhance its offerings. For Instance, in 2016 the company’s research and development expenses were approximately USD 9.5 million, 8.3% of the total revenue. Also during the same year the revenue generated from the life sciences research services segment (that provides peptide synthesis services and products) was approximately USD 91.2 million, representing an increase of 18.6% as compared to approximately USD 76.9 million for 2015.

Merck KGAA

Merck held the second position in the peptide synthesis market in 2017. The company offers a broad product portfolio of peptide synthesis reagents and custom peptide synthesis services in the market. To leverage growth opportunities in the peptide synthesis market, Merck focuses on adopting organic as well as inorganic growth strategies. For instance, in 2017, the company opened a new Life Science Center in Burlington, Massachusetts (US). The new center serves as a regional hub for scientific advancement and customer collaboration. Also in 2017, the company acquired Grzybowski Scientific Inventions (GSI). This acquisition helped the company to expand its chemical synthesis offering.

Bachem holdings

Bachem is an important player in the peptide synthesis market in 2017. The company offers catalog products that include amino acids, resins, linkers, & reagents. It also offers custom synthesis services in the market. The company aims on broadening its geographic reach by investing in strategic acquisitions, agreements, and collaborations. For instance in 2017, the company has renewed its supply agreement with AstraZeneca for the peptide active substance Goserelin. Also, in 2017 the Bachem Group entered into the collaboration with DOTTIKON ES to bring innovative, new amino acid derivatives for peptide synthesis in the market.

Geographical Growth Scenario:

The peptide synthesis market in APAC is expected to grow at the highest CAGR during the forecast period. With significant growth in the research industry in the past few years, China and India have emerged as high-growth markets peptide synthesis. The research industry in this region has grown significantly over the years; manufacturers are now focusing on providing well-established technologies to ensure sustainable and strong revenue growth from this region. Biotechnology-based drugs are anticipated to be one of the key drivers for the research industry, as reflected in the increase in research being undertaken and government funds provided for these drugs. Thus, the increasing demand for novel antibody and protein-based drugs along with growing investments by the public and private sectors in life science research are expected to drive the APAC market in the coming years.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=158927365

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledgestore” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com

Matched content

Editor’s pick

Express Press Release Distribution